We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Assessment of Potential Interactions Between Cocaine and RPR 102681 - 1

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00067535
First Posted: August 25, 2003
Last Update Posted: January 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
National Institute on Drug Abuse (NIDA)
August 21, 2003
August 25, 2003
January 12, 2017
June 2003
January 2005   (Final data collection date for primary outcome measure)
Hemodynamic response to cocaine and subjective response to cocaine [ Time Frame: 3x / 30 days ]
Not Provided
Complete list of historical versions of study NCT00067535 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Assessment of Potential Interactions Between Cocaine and RPR 102681 - 1
Potential Interactions Between IV Cocaine and RPR 102681
The purpose of this study is to assess Potential Interactions Between iv Cocaine and RPR 102681
Phase I, Double-Blind, Placebo-Controlled Dose Escalating Assessment of Potential Interactions Between Intravenous Cocaine and RPR 102681
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Diagnostic
Cocaine-Related Disorders
Drug: Cocaine-Related Disorders
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
16
June 2005
January 2005   (Final data collection date for primary outcome measure)

Inclusion Criteria:

Includes but is not limited to:

  • Non-treatment seekers
  • DSM-IV criteria for cocaine abuse or dependence
  • Ability to verbalize understanding of consent form and provide written informed consent and verbalize willingness to complete study procedures; be able to comply with protocol requirements

Exclusion Criteria:

Please contact site for more information.

Sexes Eligible for Study: All
18 Years to 45 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00067535
NIDA-CPU-0003-1
Not Provided
Not Provided
Not Provided
Not Provided
National Institute on Drug Abuse (NIDA)
Not Provided
Principal Investigator: Louis Cantilena, M.D. Uniformed Services University of Health Science
National Institute on Drug Abuse (NIDA)
February 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP